Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.67 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920112 | 0.89 | BACE1 (0.70) | BACE1KCNH2BACE2 | |
| SCHEMBL2467264 | 0.88 | BACE1 (0.73) | BACE1KCNH2BACE2 | |
| SCHEMBL2466549 | 0.88 | BACE1 (0.56) | BACE1KCNH2BACE2 | |
| SCHEMBL2465885 | 0.86 | BACE1 (0.54) | BACE1KCNH2BACE2 | |
| SCHEMBL2470718 | 0.85 | BACE1 (0.79) | BACE1KCNH2BACE2 | |
| SCHEMBL2466405 | 0.80 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| SCHEMBL2437546 | 0.80 | BACE1 (0.55) | BACE1KCNH2BACE2 | |
| SCHEMBL7909312 | 0.76 | BACE1 (0.57) | BACE1KCNH2BACE2 | |
| SCHEMBL3359171 | 0.75 | BACE1 (0.51) | BACE1KCNH2BACE2 | |
| SCHEMBL2426629 | 0.75 | BACE1 (0.58) | BACE1KCNH2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | BACE1 3/4885KCNH2 4686/4885BACE2 10/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | BACE1 6/4885KCNH2 4588/4885BACE2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.